A New Category of Metabolic Therapy:
Thermogenic Adipose Reprogramming

Our Science

Using novel RNA technology to modulate disease pathways

Targeting the underlying causes of diseases

Reprogramming metabolic function to treat diseases

Leveraging cellular crosstalk, creating amplified effects

Canary Appoints Dr. Michael Lincoff as Chief Clinical Officer to Lead Clinical Development of First-in-Class Dual Gene Silencing Therapy for Obesity

LATEST STUDY RESULTS:

CCT-217 Demonstrates Significant Weight Loss and Preserves Lean Body Mass with Potential for Single or Twice-Yearly Dosing

View more Updates

Our Mission

Pioneering transformative therapy by harnessing RNAi technology, combined with large scale human data analysis and AI, to precisely reprogram metabolic function and engineer lasting health.

Our Approach

RNAi Therapeutics: We leverage the power RNAi therapeutics to modulate gene expression and correct underlying genetic defects. These technologies offer precise and customizable treatment options for a wide range of diseases.
Reprogram Platform: Integrating three core technologies: large-scale human data analysis to ensure that our targets have strong translational relevance, AI to optimize siRNA target selection and siRNA technology to selectively 'turn off' disease-causing genes.
Act Locally, Treat Systemically: Where the therapeutic agent remains localized at the treatment site while the biological effects spread throughout the body through bioactive signaling pathways, treating the root causes of disease beyond the symptoms.
Speed to Market: Our R&D strategy which incorporates AI supported research and accelerated regulatory pathways, prioritizes speed and efficiency to deliver life-saving treatments to patients as quickly as possible.

Our Focus

Nearly every obesity drug on the market works the same way: Suppress appetite, reduce calories, lose weight. The results are temporary. The biology fights back. Muscle is lost. Weight returns. Canary takes a fundamentally different approach. Rather than telling the brain to eat less, we reprogram fat cells themselves — converting inert fat-storing tissue into high-performance, calorie-burning beige adipocytes. The body doesn’t just lose weight. It learns to burn fat as its default state.

The thermogenic revolution in metabolic medicine begins in the adipose tissue, transforming it from storage mode to energy expenditure mode — and Canary has engineered the switch.

Three Disease Areas. One Platform.
Obesity: Unlike conventional approaches, our therapies prioritize fat loss, preservation of lean body mass and body composition improvement. Our novel dual siRNA therapeutics target the energy expenditure systems - promoting the browning of white fat to increase metabolism and facilitate sustainable healthy weight loss. With the convenience of less frequent dosing and a better safety profile, this dual gene silencing therapy offers a sustainable biological solution where current therapies only offer temporary suppression.
MASH (Metabolic Dysfunction-Associated Steatohepatitis): By activating the liver’s own fat-burning signals through the adipose endocrine system, our therapies address the underlying metabolic dysfunction driving fatty liver disease and inflammation — without targeting the liver directly.
Rare Metabolic Disease: In conditions where disordered energy metabolism drives pathology, Canary’s ability to re-establish healthy metabolic balance offers a pioneering therapeutic approach for patients with Prader-Willi Syndrome, Hypothalamic Obesity, Bardet-Biedl Syndrome, and Congenital Lipodystrophy. We are developing a dual RNA metabolic restoration platform that directly modulates the gene expression pathways driving these conditions, offering a fundamentally different approach from the symptomatic strategies that families and clinicians currently rely on.

Learn more

"While the field has made vital strides in managing the behavioral symptoms of PWS, the structural and metabolic deficits have remained largely out of reach. CCT-987 changes that paradigm. A treatment that promotes weight loss while actively enhancing lean mass isn't just an improvement—it's a fundamentally different therapeutic proposition.

For these patients, achieving metabolic restoration and reversing profound muscle weakness could be absolutely life-changing.”

- Dr. Jennifer Miller, MD
Renowned Clinician and KOL in Pediatric Endocrinology and PWS

Learn more

Complex Genetic Disorders Require Multidisciplinary Approaches

Pioneering RNA Therapeutics for Metabolic Restoration

Rare metabolic genetic disorders are devastating problems for children and their families. Obesity caused by gene mutations, such as in Prader-Willi Syndrome (PWS), causes children to have an insatiable appetite and rapid weight gain. The early-onset obesity can cause cardiovascular and metabolic comorbidities and is associated with increased mortality.

PWS, a rare, complex genetic disorder requiring multi-disciplinary care currently has no cure. Our lead product, CCT-987 is designed to directly correct the peripheral adipose biology by delivering a payload of CB1R siRNA and Leptin mRNA directly to subcutaneous adipose tissue. The dual RNA therapy has the potential to achieve true metabolic restoration – driving profound improvements in the fat-to-muscle ratio and systemic metabolic parameters that far exceed the capabilities of centrally acting agents.

For more information on PWS and the search for new therapies, please visit Foundation for Prader-Willi Research.

Learn more

Energy-storing human white adipocytes before treatment

Transformation towards fat burning human beige adipocyte

CCT-217’s Remarkable Ability to Beige Human White Fat

This reprogramming of human fat cell to create metabolically active cells represents a significant breakthrough in translational adipose tissue research with profound implications for obesity therapeutics.

The first microscopic field reveals a dense population of human adipocytes which stores energy. The second picture reveals adipocytes that have undergone remarkable morphological transformation, following CCT-217 siRNA treatment into smaller, more numerous lipid droplets, in just 72 hours. The increased multilocularity (multiple small lipid droplets within cells) is characteristic of enhanced thermogenic capacity.

Beige adipose tissues predominantly function to dissipate energy surplus, increasing resting energy expenditure and counteracting obesity. This is precisely the mechanism of action in Canary’s CCT-217 which treats obesity through the transformation of our white fat into metabolically active, fat-burning beige fat.

Learn more

Harnessing the Power of Thermogenesis to Combat Obesity

By activating specific pathways involved in thermogenesis, our therapy aims to boost the body’s ability to burn calories and utilize stored fat.
Our innovative technology utilizes lipid nanoparticles (LNPs) to deliver therapeutic molecules directly to the tissues responsible for generating heat. This targeted approach aims to increase energy expenditure and promote fat burning.
This approach promotes thermogenesis (fat burning) and lipolysis (breakdown of fats), leading to more energy expenditure and broader metabolic health.

Learn more

RNA Interference (RNAi) for Therapeutic Breakthroughs

RNA interference (RNAi) is a natural cellular process that acts as a defense mechanism against viruses. It uses small interfering RNAs (siRNAs) to target and silence specific genes, effectively preventing the production of harmful proteins.
Unlike most conventional drugs, which target proteins, RNAi therapies target the root cause of disease by addressing the genetic instructions that lead to the production of faulty proteins.
This "upstream" approach allows us to tackle conditions previously considered "undruggable," opening new possibilities for treatment.
With a proven track record of safety and efficacy, RNAi represents a promising avenue for developing the next generation of targeted therapies.

Our Pipeline

Leveraging the power of RNA therapeutics to revolutionize the treatment landscape for metabolic disorders, Canary’s cutting-edge pipeline harnesses the potential of gene silencing technology to precisely target the underlying genetic causes of obesity, MASH as well as metabolic dysfunction that impact other diseases.

Learn more

Transforming Obesity Therapy

Unlike conventional approaches, our therapies prioritize fat loss, preservation of lean body mass and body composition improvement. With the convenience of less frequent dosing and a better safety profile, this siRNA offers a promising solution for individuals battling obesity and its associated metabolic complications.

Learn more

Our Team

With global industry experience, our team values collaboration, shares a passion for finding solutions to life’s biggest challenges and a desire to unlock the power of RNA therapy to transform healthcare for all.

Join our team

Latest Updates

Canary Appoints Dr. Michael Lincoff as Chief Clinical Officer to Lead Clinical Development of First-in-Class Dual Gene Silencing Therapy for Obesity

Renowned Cleveland Clinic cardiologist and lead author of the landmark SELECT trial joins Canary to advance CCT-217 into Phase 1...

Learn more

Canary Cure’s Game-Changing Obesity Therapy Burns Fat and Protects Muscle

Novel siRNA Therapeutic Demonstrates Significant Fat Loss and Remarkable Lean Body Mass Preservation, and Promises Superior Adherence New York, NY,...

Learn more

CCT-217: A Landmark Gene Silencing Therapeutic for Weight Loss That Enhances Lean Mass Composition, Reduces Visceral, Subcutaneous Fat and Restores Metabolic Health in Obesity through Browning

CCT-217 Demonstrates Significant Weight Loss and Preserves Lean Body Mass with Potential for Single or Twice-Yearly Dosing Abstract According to...

Learn more

View more Updates

Our Commitment

We are committed to advancing the field of RNAi therapy and improving the lives of patients worldwide. Our team of scientists, engineers, and clinicians is dedicated to:

Unveiling the intricate mechanisms of disease: We are deeply invested in understanding the underlying causes of metabolic dysfunctions, paving the way for more safer and effective treatments.
Expanding our pipeline of novel therapies: We are continuously learning and expanding our pipeline of innovative therapies to address a wide range of disorders, and exploring how targeting key pathways to significantly amplify metabolic activity can impact so many diseases and conditions that lack effective treatment.
Collaborating with global partners: We foster collaborations with leading research institutions and pharmaceutical companies to accelerate the development and commercialization of RNA therapies.
Advocating for novel therapeutics: We actively engage with policymakers and patient advocacy groups to promote investment in hard-to-treat diseases and cutting-edge RNA therapy as promising treatment option for patients in need.

Pioneering RNA Therapy

We are revolutionizing healthcare by harnessing the power of cutting-edge RNA therapies to develop and deliver innovative treatments that address the root causes of diseases. We are committed to fostering a culture of scientific excellence and collaboration to create life-changing treatments that are safe, effective, and accessible to all.

Disclaimer: Product candidates discussed on this website are in preclinical and/or investigational stages of development. They have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. The safety and efficacy of these investigational products have not been established, and they are not currently available for commercial.